About Us
Real-time Quotes & News
Market Analysis
Trading Platform
Terms
Promotion
FAQ
Contact
繁
简
EN
繁
简
EN
Promotion
FAQ
Contact
Open Account
Contact Us

CSI 300 index futures (IF) main contract up 0.55%; SSE 50 index futures (IH) main contract up 0.40%; CSI 500 index futures (IC) main contract up 0.84%; CSI 1000 index futures (IM) main contract up 0.86%.

2026-08-20

CSI 300 index futures (IF) main contract up 0.55%; SSE 50 index futures (IH) main contract up 0.40%; CSI 500 index futures (IC) main contract up 0.84%; CSI 1000 index futures (IM) main contract up 0.86%.

Other News
2026-08-19

U.S. heating oil futures continued to rise after EIA data showed a decrease in distillate fuel inventories, while gasoline futures fell further after EIA data showed an increase in gasoline inventories.

U.S. heating oil futures continued to rise after EIA data showed a decrease in distillate fuel inventories, while gasoline futures fell further after EIA data showed an increase in gasoline inventories.
2026-08-20

[Shandong: Focus on Developing Antibody Drugs for Treating Malignant Tumors, Hematological Diseases, etc.] The "Shandong Province Pharmaceutical Industry '15th Five-Year Plan' Development Action Plan (Draft for Comments)" is open for public comment.

[Shandong: Focus on Developing Antibody Drugs for Treating Malignant Tumors, Hematological Diseases, etc.] The "Shandong Province Pharmaceutical Industry '15th Five-Year Plan' Development Action Plan (Draft for Comments)" is open for public comment. It mentions focusing on major infectious diseases, respiratory infections, malignant tumors, drug-resistant infections, autoimmune diseases, metabolic diseases, and central nervous system diseases. The plan calls for accelerating the development of key areas such as monoclonal antibody drugs, bispecific antibodies, trispecific antibodies, antibody-drug conjugates, recombinant proteins, cell and gene therapy drugs, innovative vaccines, and marine biological drugs, promoting breakthroughs in core technologies, and accelerating industrialization. Specifically, it emphasizes the development of antibody drugs for treating malignant tumors, hematological diseases, autoimmune diseases, metabolic diseases, ophthalmic diseases, nervous system drugs, cardiovascular diseases, and anti-infective diseases. Support will be given to the development of innovative technology platforms such as multifunctional antibody drugs, antibody fusion proteins, nanobodies, combination antibodies, antibody combination preparations and high-concentration preparations, as well as novel ADC drugs, to improve industrialization capabilities.
Open Account
Demo Account
Contact Us
About Us Real-time Quotes & News Market Analysis
 Trading Platform Market Analysis Promotion Terms Promotion FAQ Contact
Copyright © 2026 Aspire Global Company Limited. All Rights Reserved.
Terms of Use and Privacy
Disclaimer

Disclaimer: ASPIRE is not responsible for the content of any analysis, advice, comment, suggestion, research report or market data in this website and links to third-party websites or resources. All the information mentioned above only represents the view of corresponding author. ASPIRE cannot and does not warrant the accuracy, validity, timeliness or completeness of any such information. You should conduct individual assessments and other proper research to make their investment decisions. The materials and information contained in this website are provided for reference only and do not constitute or form an offer, invitation, solicitation or investment advice or recommendation to acquire or dispose of any investment products or services. The price of any financial instruments described in this website may fall as well as rise. Past performance should not be taken as an indication of future performance. The risk disclosure statements do not purport to disclose or discuss all of the risks and other significant aspects of any financial instruments mentioned in this website. You should make your own appraisal of the risk and should consult to the extent necessary your own legal, tax, financial or other professional advisers in respect of any financial instruments mentioned in this website prior to entering into any transaction.

Risk Warning: Leveraged Precious Metals trading on margin carries significant risks and is not suitable for all investors. Please be sure to make investments within your own tolerance after fully understand the risks involved.

Registered & Business Address: Room 1905-1906, 19/F, Eastern Commercial Centre, 395-399 Hennessy Road, Hong Kong

Aspire Global Company Limited is not available to provide services for the residents of certain jurisdictions such as Afghanistan, the United States of America, the Islamic Republic of Iran, North Korean.